Banque Pictet & Cie SA Takes $2.03 Million Position in Soleno Therapeutics, Inc. $SLNO

Banque Pictet & Cie SA purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 43,796 shares of the company’s stock, valued at approximately $2,028,000. Banque Pictet & Cie SA owned approximately 0.08% of Soleno Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Avanza Fonder AB lifted its stake in Soleno Therapeutics by 11.2% in the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock valued at $148,000 after acquiring an additional 323 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Soleno Therapeutics by 171.9% during the 4th quarter. SG Americas Securities LLC now owns 40,198 shares of the company’s stock worth $1,861,000 after purchasing an additional 25,412 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Soleno Therapeutics during the 4th quarter valued at $17,787,000. JPMorgan Chase & Co. raised its holdings in shares of Soleno Therapeutics by 52.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 407,444 shares of the company’s stock valued at $27,543,000 after purchasing an additional 140,779 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at $301,000. Institutional investors own 97.42% of the company’s stock.

Wall Street Analyst Weigh In

SLNO has been the topic of several analyst reports. TD Cowen lowered their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a report on Tuesday, January 13th. Wall Street Zen downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Finally, HC Wainwright reduced their target price on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Some analysts and commentary say SLNO still looks attractive despite slower-than-expected U.S. launch ramp projections, supporting upside expectations for longer‑term commercial recovery. Article Title
• Neutral Sentiment: Trading flow shows unusually high options volume in SLNO, which can amplify intraday moves and explain part of the price rise; this is a short‑term liquidity/volatility signal rather than a change in fundamentals. Article Title
• Negative Sentiment: Hagens Berman filed a securities class action alleging investors were misled about DCCR and its launch disruptions; that filing cites the company’s November 2025 disclosures and could increase litigation risk and future settlement exposure. Article Title
• Negative Sentiment: A wave of law‑firm notices (Rosen, Pomerantz, Kessler Topaz, Faruqi & Faruqi, Levi & Korsinsky, Kirby McInerney, et al.) are soliciting class members and reminding investors of a May 5, 2026 lead‑plaintiff deadline — these multiple filings/solicitations keep legal risk and reputational headlines in the news cycle and can pressure sentiment. Article Title

Soleno Therapeutics Price Performance

NASDAQ SLNO opened at $39.49 on Friday. The stock has a 50-day simple moving average of $37.86 and a 200 day simple moving average of $47.96. Soleno Therapeutics, Inc. has a twelve month low of $29.43 and a twelve month high of $90.32. The stock has a market capitalization of $2.04 billion, a PE ratio of 171.70 and a beta of -2.81. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.